Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL682819 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL659743 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| Methane SCHEMBL27798790 | 0.98 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL4772964 | 0.98 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| Trifluoroacetic Acid SCHEMBL2267360 | 0.87 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL1553169 | 0.86 | MAOB (0.50) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL1553074 | 0.86 | MAOB (0.50) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL8924483 | 0.84 | DRD4 (0.51) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL78044 | 0.84 | DRD4 (0.51) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL28529628 | 0.84 | SLC6A2 (0.41) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989188-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2015-07-22 | — | — | EP | disclosed |
| EP-2562168-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2014-04-16 | — | — | EP | disclosed |
| US-20140038945-A1 | PIPERAZINE PDE4 INHIBITORS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2014-02-06 | — | — | US | disclosed |
| US-8501745-B2 | Piperazine PDE4 inhibitors and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-08-06 | — | — | US | disclosed |
| EP-2562168-A1 | Therapeutic piperazines as PDE4 inhibitors | Helicon Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| CN-101490017-B | Therapeutic piperazines as pde4 inhibitors | HELICON THERAPEUTICS INC | 2013-01-23 | — | — | CN | disclosed |
| US-8338405-B2 | Therapeutic piperazines | DART NEUROSCIENCE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| EP-1844026-B1 | MORPHOLINES AS 5HT2C AGONISTS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | disclosed |
| EP-1844026-B1 | MORPHOLINES AS 5HT2C AGONISTS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | disclosed |
| US-20110065688-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE LLC | 2011-03-17 | — | — | US | disclosed |
| CN-101490017-A | Therapeutic piperazines as PDE4 inhibitors | HELICON THERAPEUTICS INC (US) | 2009-07-22 | — | — | CN | disclosed |
| EP-1989188-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | Helicon Therapeutics, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| EP-1844026-A2 | MORPHOLINES AS 5HT2C AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007100852-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070203124-A1 | Therapeutic Piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006077025-A2 | MORPHOLINES AS 5HT2C AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203124-A1 | Therapeutic Piperazines | PDE4A, PDE4B, PDE12 | SLC6A2 894/4885SLC6A3 654/4885SLC6A4 166/4885 |
| US-20110065688-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE12 | SLC6A2 894/4885SLC6A3 654/4885SLC6A4 166/4885 |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HTR2C, HTR1A, HTR1B | SLC6A2 186/4885SLC6A3 335/4885SLC6A4 89/4885 |
| US-20140038945-A1 | PIPERAZINE PDE4 INHIBITORS AND USES THEREOF | PDE4A, PDE12, PDE4B | SLC6A2 1198/4885SLC6A3 905/4885SLC6A4 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.